Development of a SARS-CoV-2 neutralization assay based on a pseudotyped virus using a HIV system

Abstract

Regarding the extensive global attention to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that constitutes an international public health emergency, pseudovirus neutralization assays have been widely applied due to their advantages of being able to be conducted in biosafety level 2 laboratories and having a high safety factor. In this study, by adding a blue fluorescent protein (AmCyan) gene to the HIV system pSG3-△env backbone plasmid HpaI and truncating the C-terminal 21 amino acids of the SARS-CoV-2 spike protein (S), high-titer SARS-CoV-2-Sdel21-AmCyan fluorescent pseudovirus was successfully packaged. The fluorescent pseudovirus was used to establish a neutralization assay in a 96-well plate using 293T cells stably transfected with the AF cells. Then, parameters such as the ratio of backbone and membrane plasmid, sensitive cells, inoculation of cells and virus, as well as incubation and detection time were optimized. The pseudovirus neutralization assay demonstrated high accuracy, sensitivity, repeatability, and a strong correlation with the luminescent pseudovirus neutralization assay. Additionally, we scaled up the neutralizing antibody determination method by increasing the plate size from 96 wells to 384 wells. We have established a robust fluorescent pseudotyped virus neutralization assay for SARS-CoV-2 using the HIV system, providing a foundation for serum neutralization antibody detection, monoclonal antibody screening, and vaccine development.

Keywords

fluorescent pseudovirus / HIV system / neutralization assay / SARS-CoV-2

References

1	JT Wu, K Leung, GM Leung. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689-697.
2	DS Hui, E IA, TA Madani, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-266.
3	B Hu, H Guo, P Zhou, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154.
4	J Nie, Q Li, J Wu, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020;15(11):3699-3715.
5	H Xiong, Y Wu, J Cao, et al. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg Microbes Infect. 2020;9(1):2105-2113.
6	J Chan, K Kok, Z Zhu, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-236.
7	D Wrapp, N Wang, KS Corbett, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-1263.
8	AC Walls, YJ Park, MA Tortorici, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-292.
9	J Shang, G Ye, K Shi, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221-224.
10	Q Wang, Y Zhang, L Wu, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894-904.
11	M Yuan, N Wu, X Zhu, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368(6491):630-633.
12	Z Huang, J Chai. Door to the cell for COVID-19 opened, leading way to therapies. Signal Transduct Target Ther. 2020;5(1):104.
13	H Yang, Z Rao. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021;19(11):685-700.
14	ED Anderson, SS Molloy, F Jean, et al. The ordered and compartment-specfific autoproteolytic removal of the furin intramolecular chaperone is required for enzyme activation. J Biol Chem. 2002;277(15):12879-12890.
15	VK Kibirev, TV Osadchuk, L Radavski? Iu. Furin and its biological role. Ukr Biokhim Zh (1999). 2007;79(6):5-18.
16	G Thomas. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002;3(10):753-766.
17	A Hasan, BA Paray, A Hussain, et al. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. Biomol Struct Dyn. 2021;39(8):3025-3033.
18	ME Dieterle, D Haslwanter, RH Bortz, et al. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. Cell Host Microbe. 2020;28(3):486-496.
19	S Fukushi, T Mizutani, M Saijo, et al. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol. 2005;86(Pt 8):2269-2274.
20	WC Schwegmann, J Glende, X Ren, et al. Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and a human coronavirus. J Gen Virol. 2009;90:1724-1729.
21	PW Parren, DR Burton. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol. 2001;77:195-262.
22	MM Coughlin, BS Prabhakar. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol. 2012;22(1):2-17.
23	J Nie, Q Li, J Wu, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680-686.
24	GR Deshpande, GN Sapkal, BN Tilekar, et al. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. Indian J Med Res. 2020;152(1 & 2):82-87.
25	H Chen, C Huang, L Tian, et al. Cytoplasmic tail truncation of SARS-CoV-2 spike protein enhances titer of pseudotyped vectors but masks the effect of the D614G mutation. J Virol. 2021;95(22):e0096621.
26	M Cevik, K Kuppalli, J Kindrachuk, et al. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862.
27	Q Li, Q Liu, W Huang, et al. Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol. 2018;28(1):e1963.
28	J Nie, X Wu, J Ma, et al. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci Rep. 2017;7:42769.
29	Y Wang, J Ma, J Nie et al,. Pseudovirus packaging system and applications: CN104830908B [P]. 2018 (in Chinese).
30	C Dai, Z Cao, Y Wu, et al. Improved fusion protein expression of EGFP via the mutation of both Kozak and the initial ATG codon. Cell Mol Biol Lett. 2007;12(3):362-369.
31	S Funke, A Maisner, MD Mühlebach, et al. Targeted cell entry of lentiviral vectors. Mol Ther. 2008;16(8):1427-1436.
32	C Schwegmann-We?els, J Glende, X Ren, et al. Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and a human coronavirus. J Gen Virol. 2009;90(Pt 7):1724-1729.
33	L Zhang, CB Jackson, H Mou, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11(1):6013.
34	D Weissman, MG Alameh, T de Silva, et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe. 2021;29(1):23-31.. e4.
35	Y Wang, Z Zhou, X Wu, et al. Pseudotyped viruses. Adv Exp Med Biol. 2023;1407:1-27.
36	BP Cormack, RH Valdivia, S Falkow. FACS-optimized mutants of the green fluorescent protein (GFP). Gene. 1996;173(1):33-38. Spec No.
37	A Crameri, EA Whitehorn, E Tate, et al. Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat Biotechnol. 1996;14(3):315-319.
38	V Sample, RH Newman, J Zhang. The structure and function of fluorescent proteins. Chem Soc Rev. 2009;38(10):2852-2864.
39	F Uliczka, F Pisano, A Kochut, et al. Monitoring of gene expression in bacteria during infections using an adaptable set of bioluminescent, fluorescent and colorigenic fusion vectors. PLoS One. 2011;6(6):e20425.
40	O Guryev, MC Jaimes, MG Edinger, et al. Use of a new violet-excitable AmCyan variant as a label in cell analysis. Cytometry Part A. 2012;81(7):627-634.